Loading viewer...
earnings
Format: PDF earnings
Halozyme Therapeutics reported Q4 and FY 2023 financial results, highlighting its industry-leading ENHANZE® drug delivery platform with 7 approved partnered products in 100+ countries and approximately 800,000 patients treated. The company provides guidance for 2024 and a longer-term outlook through 2028, emphasizing platform expansion and development of a high-volume auto-injector.
investor_presentation
31 Pages
earnings
19 Pages
Evertec
Max Financial Services Q1 FY23 Earnings Update
earningsearnings
53 Pages
Max Financial Services
Philip Morris International 2016 Q2 Earnings Results
earningsearnings
37 Pages
Philip Morris International
Occidental Petroleum Q1 2024 Earnings Call
earningsearnings
45 Pages
Occidental Petroleum Corporation
AIA Engineering Q2 FY2021 Earnings Presentation
earningsearnings
9 Pages
AIA Engineering Limited